#1 Clinical Trials Search in Europe

Study Comparing Standard Chemotherapy with Letrozole and Abemaciclib for High/Intermediate Risk HR-Positive, HER2-Negative Breast Cancer Patients

2 1 1 1

What is this study about?

This clinical trial is focused on studying a type of breast cancer known as hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative breast cancer. This type of cancer is considered to be at high or intermediate risk and requires treatment before surgery, known as neoadjuvant therapy. The study aims to compare the effectiveness and safety of two different treatment approaches. One group of patients will receive standard chemotherapy, while the other group will receive a combination of two medications: letrozole and abemaciclib (also known by its code name LY2835219), which is provided in the form of Verzenios 50 mg film-coated tablets.

The purpose of the study is to evaluate how well these treatments work in reducing the amount of cancer left after treatment, known as the Residual Cancer Burden (RCB). Patients will be randomly assigned to one of the two treatment groups. The study will involve taking the assigned medication for a period of time before undergoing surgery to remove the breast cancer. Throughout the study, patients will have regular check-ups and tests to monitor their health and the effectiveness of the treatment. The study will also look at other factors, such as changes in a protein called Ki67, which is related to how quickly cancer cells are growing.

This trial is designed to help doctors understand which treatment option is more effective and safer for patients with this specific type of breast cancer. The study will continue for several years to gather enough information to make a clear comparison between the two treatment methods. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.

1 joining the study

Upon joining the study, you will be randomly assigned to one of two treatment groups. This means you will either receive the standard chemotherapy or a combination of letrozole and abemaciclib.

You will be informed about the specific treatment you will receive and any potential side effects.

2 treatment phase

If you are in the group receiving letrozole and abemaciclib, you will take Verzenios 50 mg film-coated tablets orally. The dosage and frequency will be explained to you by the medical team.

The treatment will be administered as a neoadjuvant therapy, which means it is given before surgery to help shrink the tumor.

3 monitoring and assessments

Throughout the treatment, regular monitoring will be conducted to assess your response to the therapy. This includes blood tests, imaging studies, and other necessary evaluations.

The main goal is to evaluate the Residual Cancer Burden (RCB), which measures the amount of cancer remaining after treatment.

4 surgery preparation

After completing the neoadjuvant therapy, you will be prepared for surgery. The type of surgery will depend on the response to the treatment and the surgeon’s assessment.

A sentinel lymph node biopsy (SLNB) may be performed to check for cancer spread to the lymph nodes.

5 post-treatment follow-up

Following surgery, you will have follow-up visits to monitor your recovery and any long-term effects of the treatment.

Additional tests may be conducted to ensure there is no recurrence of cancer and to evaluate your overall health.

Who Can Join the Study?

  • Provide written informed consent before any study procedures begin.
  • Be a woman aged 18 years or older.
  • Have a confirmed diagnosis of primary invasive adenocarcinoma of the breast. This is a type of breast cancer that starts in the glandular tissue.
  • Have a sample of the primary tumor available for testing before treatment.
  • Have breast cancer that is hormone receptor (HR) positive and HER2 negative. This means the cancer grows in response to hormones but does not have too much of the HER2 protein.
  • Be considered at intermediate or high risk based on a test called the Ki67 index, which measures how quickly cancer cells are growing.
  • Be in certain stages of breast cancer as defined by the TNM Classification, which describes the size and spread of the cancer.
  • If diagnosed with multiple areas of breast cancer, at least two tumor areas should be biopsied, and all must meet the HR positive and HER2 negative criteria.
  • Have an indication for neoadjuvant treatment, which is therapy given before the main treatment, usually surgery.
  • Be a candidate for surgery that aims to cure the cancer, as assessed by a surgeon.
  • If a sentinel lymph node biopsy (SLNB) was done before treatment, it must show no cancer spread (negative result).
  • Be either premenopausal or postmenopausal. Postmenopausal status is defined by certain criteria, such as age or surgical removal of ovaries.
  • Have an ECOG performance status of 0 or 1, which means being fully active or restricted in physically strenuous activity but able to carry out light work.
  • Be able to swallow oral medications.
  • Have adequate function of organs and bone marrow, as shown by specific blood test results.
  • Have a left ventricular ejection fraction (LVEF) of 50% or higher, which measures how well the heart pumps blood.
  • For premenopausal women, agree to use effective non-hormonal birth control methods during the study and for a short period after.
  • Have a negative pregnancy test before starting treatment if premenopausal or recently menopausal.
  • Agree to provide biological samples for research purposes.
  • Be willing and able to attend scheduled visits, follow the treatment plan, and undergo necessary tests and procedures.

Who Cannot Join the Study?

  • Patients who do not have high/intermediate risk hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative breast cancer.
  • Patients who are not indicated for neoadjuvant therapy (treatment given before the main treatment to shrink a tumor).
  • Patients who are not female.
  • Patients who are considered part of a vulnerable population, which may include those who are unable to give informed consent or are at higher risk of harm.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Hospital Universitario Y Politecnico La Fe Valencia Spain
Hospital Clinico San Carlos Madrid Spain

Other Sites

Site Name City Country Status
Hospital General Universitario Gregorio Maranon Madrid Spain
Hospital General Universitario Morales Meseguer Murcia Spain
Fundacion Instituto Valenciano De Oncologia Valencia Spain
Hospital San Pedro De Alcantara Caceres Spain
Hospital Universitario De Jaen Jaen Spain
Hospital Clinico Universitario Lozano Blesa Zaragoza Spain
Consorcio Hospitalario Provincial De Castellon Castello De La Plana Spain
Virgen del Rocío University Hospital Sevilla Spain
Hospital Alvaro Cunqueiro Vigo Spain
Area De Salud De Burgos Y Soria Burgos Spain
Hospital Universitario Virgen De La Victoria Malaga Spain
Hptsodsh Uqijqnipzsrvy Muhksnm Dt Vwfaeyfrjx Santander Spain
Irguamne Czvzrv Dykiwgkfqomswinrp L'hospitalet De Llobregat Spain
Hopzgsve Ubzkngcpnbksn Dt Bnggzow Badajoz Spain
Hvhjkpoh Uhkocxixrlbml Dygmubrt Donostia / San Sebastian Spain
Huggmgyt Usbbdvmairwgx ds A Cnsnxz A Coruna Galicia Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Spain Spain
Not recruiting
01.06.2020

Trial locations

Investigated drugs:

Letrozole is a medication used in the treatment of breast cancer. It works by lowering the levels of estrogen in the body, which can help slow or stop the growth of certain types of breast cancer cells that need estrogen to grow. In this trial, letrozole is being used as part of a combination therapy to see if it can help reduce the size of the cancer before surgery.

Abemaciclib is a medication that helps treat breast cancer by blocking certain proteins in cancer cells, which can slow down or stop their growth. It is used in combination with other treatments to see if it can improve the effectiveness of the therapy in reducing the cancer before surgery.

Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer – This type of breast cancer is characterized by the presence of hormone receptors for estrogen or progesterone and the absence of excess HER2 protein. It typically grows in response to hormones and progresses at a variable rate depending on the hormonal environment. The cancer may initially be confined to the breast tissue but can spread to nearby lymph nodes and other parts of the body over time. The progression is often monitored by changes in tumor size and the presence of cancer cells in lymph nodes. The disease can be classified into different stages based on the size of the tumor and the extent of spread. The response to treatment is often evaluated by measuring the reduction in tumor size and the presence of residual cancer cells after therapy.

Trial ID:
2024-514395-40-00
Protocol code:
GEICAM/2019-01
NCT ID:
NCT04293393
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • A Study Comparing GDC-4198 Alone and with Giredestrant versus Abemaciclib with Giredestrant for Advanced Breast Cancer After Previous CDK4/6 Treatment

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

  • Study of patritumab deruxtecan versus drug combination in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Greece Hungary Italy Poland +1